GlassScriptPhysician profile
Malina C Patel
NPI 1679196737
$2,064.83
in general payments reported to CMS, 2019-2025
12 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $469 · 2024: $1,120 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $514.49 | 2023-2024 | Orladeyo |
| Dermavant Sciences, INC. | $318.59 | 2023-2024 | Vtama |
| Csl Behring | $269.76 | 2024-2025 | Haegarda, Hizentra, Andembry |
| Alk-Abello, INC | $206.44 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $201.01 | 2023-2024 | Tezspire |
| Genentech USA, INC. | $143.53 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $136.10 | 2025 | |
| Blueprint Medicines Corporation | $112.02 | 2024 | Ayvakit |
| Organon LLC | $62.17 | 2025 | Vtama |
| Genzyme Corporation | $53.87 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.84 | 2024 | Hyqvia |
| Astellas Pharma US INC | $16.01 | 2024 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.